WFA
PHAT icon

Wipfli Financial Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Wipfli Financial Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+115
New +$1.1K ﹤0.01% 2475

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wipfli Financial Advisors's PHAT Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Phathom Pharmaceuticals (PHAT) in Q3 2022: 115 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2475 among its holdings.

94 funds tracked by Wall St. Rank hold PHAT as of Q3 2022.

  • Wipfli Financial Advisors held 115 shares of Phathom Pharmaceuticals worth $1K as of Q3 2022.
  • Phathom Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
  • Phathom Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2475 holding.
  • 94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.